Savara Inc (SVRA) gains 0.73% for July 21

Equities Staff  |

Savara Inc (NASDAQ: SVRA) shares gained 0.73%, or $0.01 per share, to close Wednesday at $1.39. After opening the day at $1.41, shares of Savara fluctuated between $1.41 and $1.38. 284,676 shares traded hands a decrease from their 30 day average of 1,017,625. Wednesday's activity brought Savara’s market cap to $158,251,936.

Savara is headquartered in West Lake Hills, Texas..

About Savara Inc

Savara is an orphan lung disease company. Its lead program, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Its management team has significant experience in orphan drug development and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization.

Visit Savara Inc’s profile for more information.

About The Nasdaq Stock Market

The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world's leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information on Savara Inc and to follow the company’s latest updates, you can visit the company’s profile page here: Savara Inc’s Profile. For more news on the financial markets be sure to visit Equities News. Also, don’t forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Market Movers

Sponsored Financial Content